Eventos
FAPESP-RSC-MMV-DNDi workshop “Frontiers in Science on Neglected Diseases”
13 - 14 November 2014
FAPESP, the São Paulo Research Foundation, is hosting a conference on neglected diseases in collaboration with the Royal Society of Chemistry, Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV). The aim of the conference is to bring together Brazilian and international scientists (from pharmaceutical companies, universities and product development partnerships) working in drug research targeted on kinetoplastid diseases or malaria. The objectives include sharing expertise and learnings as well as building relationships that could be the basis for future collaborations.
According to the World Health Organization (WHO), Neglected Tropical Diseases (NTDs) affect more than 1 billion people worldwide and constitute an important cause of morbidity and mortality, representing 10.5% of the global disease burden.
In January 2012, WHO launched a new roadmap for the control and elimination of NTDs between now and 2020, and the e London Declaration, signed by a group of public and private actors, supports these efforts. Of the 17 NTDs listed by the WHO, 14 are present in Brazil. Among these, the kinetoplastids, such as Chagas disease and leishmaniasis, have a particularly high unmet medical need. Despite this, according to the G-finder 2013 Report, in 2012 only 4.3% of the total R&D funding for neglected diseases was dedicated to this group of diseases. A further two diseases of global importance, malaria and tuberculosis, have also been added to the list of neglected diseases by the Brazilian Health Industrial Complex Executive Group (Grupo Executivo do Complexo Industrial da Saúde - GECIS) thus defining a priority set of diseases for research and development in the country.
Brazil has a key role to play in the fight against neglected diseases, not only in aligning with WHO recommendations, but also by contributing experience, scientific and technical knowledge, innovative alternatives and technological development, especially by tapping the expertise existing in the research community in the State of São Paulo.
Among the new R&D initiatives that have been launched over the last 15 years by a broad range of stakeholders including governments, private foundations, academic groups and pharmaceutical companies, both in emerging and developing countries, the emergence of non-profit Product Development Partnerships (PDPs) has been significant. These organizations are driving neglected disease R&D, managing global portfolios of research projects and products in their pipelines.
DNDi and MMV are the two such PDPs focused on discovering and delivering new, affordable medicines for endemic populations suffering with kinetoplastid diseases and malaria respectively. FAPESP is an independent public foundation whose mission is to foster research and the scientific and technological development of the State of São Paulo.
The Royal Society of Chemistry is the world’s leading chemistry community, advancing excellence in the chemical sciences. It has 48,000 members and a knowledge business that spans the globe. A not-for-profit organisation, the Royal Society of Chemistry works to shape the future of the chemical sciences, for the benefit of science and humanity.
In forming this alliance, these four organizations hope to promote scientific solutions to problems of people in need around the world. As the hosting institution for this workshop, FAPESP will be announcing potential future collaboration projects involving DNDi, the Royal Society of Chemistry and MMV.
Venue:
FAPESP: Rua Pio XI, 1500
Alto da Lapa, São Paulo, Brazil
Dates and times:
November 13th: 8:30 - 17:30
November 14th: 9:00 - 12:30
Registration: www.fapesp.br/eventos/find/registration
PROGRAM
November 13: Frontiers in Science on Neglected Diseases
Scientific Presentations and Roundtable Discussion
|
09.00 |
Welcome FAPESP, RSC, DNDi, MMV |
Carlos Henrique de Brito Cruz (FAPESP), Alejandra Palermo (RSC), Rob Don (DNDi) and Jeremy Burrows (MMV) |
|
Session 1: Setting the Scene |
Chairs: Rob Don (DNDi) and Jeremy Burrows (MMV) |
|
|
09.30 |
Introduction to the Product Development Partnership (PDP) model: MMV and DNDi |
Paul Willis (MMV) and Charlie Mowbray (DNDi) |
|
09.45 |
Neglected Diseases Landscape in Brazil and South America |
Jeffrey Jon Shaw (USP) |
|
10:00 |
Drug Discovery for Neglected Diseases |
Adriano Andricopulo (IFSC-USP) |
|
10:10 |
Chagas Disease: recent clinical developments |
Sergio Sosa-Estani (DNDi) |
|
10:20 |
Malaria the disease: A short introduction |
Sergio Wittlin (STPH) |
|
10:30 |
Drug Discovery in Brazil, Challenges and Opportunities |
Simon Campbell (MMV and RSC) |
|
10:50 |
Questions and discussion |
All |
|
11:00 |
Coffee break |
|
|
|
Session 2: talks 15 mins MAX: 10 mins + 5 mins Q&A [no more than 10 slides] on presenter’s area of expertise |
Chair: Eric Chatelain (DNDi) |
|
11:30 |
Drug Discovery for Neglected Tropical Diseases |
Ian Gilbert (Dundee Drug Discovery Unit) |
|
11:45 |
HCS as a strategy for the development of physiologically relevant drug assays |
Lucio Freitas (LNbio - CNPEM) |
|
12:00 |
Drug metabolism and pharmacokinetics – An introduction |
Sonia De Morais (Abbvie) |
|
12:15 |
CD8+ T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development? |
Mauricio Martins Rodrigues (UNIFESP) |
|
12:30 |
Lunch and Networking session |
|
|
|
Session 3: |
Chair: Walter Colli (FAPESP) |
|
14:00 |
Targets for drug development |
Ariel Mariano Silber (IQ - USP) |
|
14:15 |
Discovery and Development of Novel Benzoxaboroles to Treat Kinetoplastid Diseases. |
Bob Jacobs (Anacor) |
|
14:30 |
Recent collaborations with Drugs for Neglected Diseases initiative-DNDi and with Medicines for Malaria Venture-MMV in the area of neglected diseases |
Luiz Carlos Dias (Unicamp) |
|
14:45 |
Druggability of the Cofactor Metabolism in Malaria |
Carsten Wrenger (USP) |
|
15:00 |
Open Innovation and Mode of Action Tools for Kinetoplastid and Malaria Drug Discovery |
Javier Gamo (GSK) |
|
15:15 |
From fluorescent flowers to fluorescent parasites |
Erick L. Bastos (IQ/USP) |
|
15:30 |
Coffee break |
|
|
|
Session 4: |
Chair: Eric Stobbaerts (DNDi) |
|
16.00 |
Cheminformatics and Bioinformatics Approaches Applied to Tropical Diseases |
Andreas Bender (Cambridge) |
|
16.15 |
Selective estrogen receptor modulators: alternative drugs for the treatment of leishmaniasis |
|
|
16.30 |
Generation and analysis of the immunogenicity of recombinant proteins based on the different allelic forms of the circumsporozoite antigen of Plasmodium vivax aiming at the development of a universal vaccine against malaria. |
Mauricio Martins Rodrigues (UNIFESP) |
|
16:45 |
Closing words |
Alejandra Palermo (RSC) |
|
17:00 |
Reception at FAPESP |
All participants |
|
18:30 |
End of Day 1 |
November 14: Frontiers in Science on Neglected Diseases
Fostering Collaborations
|
09:00 |
Welcome to Day 2: Reflections on the story so far… |
Simon Croft (LSHTM) |
|
Session 6: |
Chair: Glaucius Oliva (CNPq) |
|
|
09:15 |
Drug discovery and the epidemiology of Chagas disease |
Bianca Zingales (USP) |
|
09:30 |
From Drug Repositioning to Natural Products against Leishmaniasis and Chagas Disease |
Andre Gustavo Tempone (Adolfo Lutz Institute) |
|
09:45 |
Protein structure based approaches to inhibit Plasmodium DHODH for malaria |
Peter Johnson (Leeds) |
|
10:00 |
Unveiling Plasmodium vivax Biology: Challenges and Perspectives |
Fábio Trindade Maranhão Costa (Unicamp) |
|
10:15 |
Prodrug design and rational drug design |
Elizabeth Igne Ferreira (USP) |
|
10:30 |
Coffee break |
|
|
|
Session 7: |
Chair: Javier Gamo (GSK) |
|
11:00 |
A platform to expand chemical and target space for neglected diseases: The academic model by QHETEM |
Flavio da Silva Emery (USP) |
|
11:15 |
DMPK challenges for neglected diseases: lipoidal permeability governs PK properties. |
Dennis Smith (MMV) |
|
11:30 |
Structure-Activity Relationships of Potent Noncovalent Cruzain Inhibitors as Anti-Trypanosoma cruzi Agents. |
Adriano Andricopulo (IFSC-USP) |
|
11:45 |
MMV390048 Case study - Delivery of a Clinical Candidate for Malaria |
Kelly Chibale (UCT), Sergio Wittlin (STPH) and Susan Charman (Monash) |
|
12.30 |
Closing words and Lunch |
Carlos Henrique de Brito Cruz (FAPESP) and Simon Campbell (RSC) |
November 14: Developing Potential Collaborations on Neglected Diseases
Closed section, by invitation only
|
|
Roundtable discussion (closed session) |
Chair: Simon Campbell and Carlos Henrique de Brito |
|
14.00 |
Potential collaborations - Next steps Establishing Partnerships and information on Mechanisms for Funding |
Representatives from FAPESP, MMV, DNDi and RSC only. |
|
17.00 |
End |
Event free of charge / Limited registration
Information
Tel.: (11) 3838-4216
meletti@fapesp.br
Parking suggestion:
Pio Park - Rua Pio XI, 1320
Tonimar - Rua Jorge Americano, 89